Logo

UCB Acquires Handl Therapeutics to Augment its Gene Therapy Portfolio

Share this

M&A

UCB Acquires Handl Therapeutics to Augment its Gene Therapy Portfolio

Shots:

  • The acquisition will bolster UCB’s pipeline program- capabilities- and platforms in the gene therapy space. The Handl Therapeutics will continue to be based in Leuven- Belgium while working closely with UCB’s international research teams
  • In addition- the UCB collaborated with Lacerta to focus on CNS diseases- under which Lacera will lead research- preclinical activities- and the early manufacturing process development- while UCB will complete IND-enabling studies- manufacturing- and clinical development
  • The collaboration will allow UCB to access Lacerta’s expertise in AAV-based CNS targeted gene therapies- fortifying UCB's ability to produce effective treatments for neurodegenerative diseases

­  Ref: PRNewswire | Image: The Pharma Letter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions